TL;DR
This paper outlines a randomized, open-label clinical trial protocol designed to compare the long-term efficacy of entecavir versus tenofovir disoproxil fumarate (TDF) in preventing the recurrence of hepatocellular carcinoma (HCC) and viral reactivation in patients who have undergone curative resection for HBV-associated HCC. The study aims to provide robust evidence to guide treatment decisions for this vulnerable patient population.
What Problem Does This Paper Address?
Hepatitis B virus (HBV) infection is a major global health concern, significantly increasing the risk of cirrhosis and hepatocellular carcinoma (HCC). For patients diagnosed with HBV-associated HCC, curative resection is a primary treatment option. However, a critical challenge remains the high risk of HCC recurrence and HBV reactivation even after successful surgery. Entecavir and tenofovir disoproxil fumarate (TDF) are standard first-line antiviral treatments recommended to mitigate these risks. While their short-term efficacy is established, there's ongoing controversy and a lack of definitive evidence regarding their long-term comparative effectiveness in preventing HCC recurrence and viral reactivation specifically in the post-hepatectomy setting. Existing studies, including meta-analyses, have yielded conflicting conclusions, highlighting the need for a well-designed, large-scale, randomized controlled trial with extended follow-up.
Methods
This study is designed as a randomized, open-label, superiority trial. A total of 240 participants will be recruited from three hospitals in Guangxi province, China, an area with a high incidence of HCC. Participants will be randomly assigned in a 1:1 ratio to receive either entecavir monotherapy or TDF monotherapy. The treatment will be administered peri- and post-operatively.
The primary outcome of the study is recurrence-free survival at 1, 3, and 5 years after curative hepatectomy. This is defined as the time from randomization to the first occurrence of HCC recurrence, which can be either extrahepatic or a new intrahepatic tumor, as detected by imaging.
Secondary outcomes include:
- Overall survival at 1, 3, and 5 years.
- Incidence and severity of adverse events, assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
- Virological response, measured by HBV DNA titers.
- Rate of alanine transaminase (ALT) normalization.
- Seroreactivity (presence of HBsAg or HBV e antigen) at 24 and 48 weeks post-surgery.
- Treatment tolerability, assessed by the proportion of patients completing the planned treatment.
Participants will undergo regular follow-up assessments, including blood tests (liver function, renal function, HBV DNA, etc.), and imaging (ultrasonography, CT/MRI of the chest and abdomen).
Randomization will be stratified by sex, tumor stage, and preoperative HBV DNA titer to ensure balanced groups. Blinding will be limited to investigators and participants; data analysts will remain blinded to group allocation.
Datasets
Not discussed in the paper. The study focuses on prospective data collection from enrolled participants.
Key Insights and Ideas
- The critical need for long-term comparative data: The paper strongly emphasizes that while short-term benefits of entecavir and TDF are known, their long-term impact on preventing HCC recurrence after surgery remains a significant clinical question with conflicting evidence.
- Focus on a high-risk population: By specifically targeting patients who have undergone curative resection for HBV-associated HCC, the study addresses a group with a particularly high risk of adverse outcomes.
- Rigorous trial design: The use of a randomized, open-label, superiority trial design with a substantial follow-up period (up to 5 years) is crucial for generating reliable evidence to resolve existing controversies.
- Comprehensive outcome assessment: The inclusion of multiple primary and secondary outcomes, ranging from survival rates to virological markers and adverse events, provides a holistic view of the drugs' efficacy and safety.
Key Results
As this is a study protocol, no results are presented. The paper outlines the planned methodology for generating future results.
Limitations and Future Work
Limitations acknowledged by the authors: * Open-label design: While participants and investigators know the assigned treatment, this is a common limitation in trials where blinding is not feasible or ethical. Data analysts are blinded to mitigate bias. * Potential for treatment conversion requests: Participants knowing their assigned treatment might request to switch, potentially leading to their exit from the study. * Funding constraints impacting sample size: The authors mention that their initial plan for a larger sample size (638 cases) was not approved by the Ethics Committee due to funding concerns, raising a potential risk that the current sample size might not be sufficient to achieve all intended objectives with maximum power. * No specific post-trial care provisions: The study does not offer specific post-trial care beyond standard recommendations.
Future Work suggested by the paper: * The study itself is the future work, aiming to provide definitive evidence on the comparative long-term efficacy of entecavir and TDF. * The protocol mentions that data analysis will be published at conferences and in peer-reviewed journals, and that full protocols, participant-level data, and statistical code will be made publicly available after publication.
Summary updated